Quest Diagnostics Boosts FY23 Adj. EPS, Revenue Outlook - Update
(RTTNews) - While reporting financial results for the second quarter on Wednesday, Quest Diagnostics Inc. (DGX) raised its adjusted earnings and revenue guidance for the full-year 2023.
For fiscal 2023, the company now projects earnings in a range of $7.52 to $7.92 per share and adjusted earnings in a range of $8.50 to $8.90 per share on net revenues between $9.12 billion and $9.22 billion.
Previously, the company expected earnings in the range of $7.52 to $8.02 per share and adjusted earnings in the range of $8.45 to $8.95 per share on net revenues between $8.93 billion and $9.08 billion.
On average, analysts polled by Thomson Reuters expect the company to report earnings of $8.69 per share on revenues of $9.06 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Haystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer Therapy
Quest Diagnostics To Acquire Outreach Laboratory Services Of OhioHealth
Quest Diagnostics To Acquire LifeLabs From OMERS In About $985 Mln Deal
Quest Diagnostics Awarded Contract To Assess Burden Of Hepatitis C Virus In U.S By CDC
Quest, Scipher Team Up To Expand Diagnostic Services Access For Patients With Rheumatoid Arthritis
Quest Diagnostics Narrows FY23 Adj. EPS Outlook Range, Boosts Revenue Forecast - Update
Quest Diagnostics Says FDA Grants Breakthrough Designation For Adeno-associated Virus Test
